What is cagrilintide and how does it differ from semaglutide Cagrilintide: Long-acting amylin analog What cagrilintide is: Synthetic analog of amylin (human hormone) Long-acting formulation (weekly dosing) Developed by Novo Nordisk Currently in Phase 3 clinical trials Not yet FDA approved (as of 2024) Paired with semaglutide as "CagriSema" How amylin works naturally: Co-secreted with insulin from pancreatic beta cells Released after meals Slows gastric emptying (food stays in stomach longer) Reduces glucagon secretion Signals satiety to brain Regulates postprandial glucose Cagrilintide's mechanisms: Mimics natural amylin but lasts much longer Dramatically slows gastric emptying Increases satiety and fullness Reduces food intake Lowers postprandial glucose Works on amylin receptors (different from GLP-1) Primary benefits: Powerful appetite suppression Extended feeling of fullness Reduced meal frequency Lower caloric intake Glucose regulation Complements GLP-1 action Learn about peptides , how peptides work , and what are peptides used for in our foundational guides

The new approval for Retevmo, which was previously authorized to treat patients 12 and older with RET-positive thyroid cancers, is based on a single-arm study that showed an overall response rate of 48%, with a median duration of response not reached after 12 months of follow-up
A Randomized controlled trial (RCT) has demonstrated that LF supplementation enhances the integrity of the tear film, improves the morphology of conjunctival epithelial cells, and increases the lipid layer thickness, contributing to overall tear stability (Samuelsen et al., 2004)
Reported side effects are generally mild and may include: Redness, swelling, or discomfort at the injection site Mild headache Fatigue (usually short-lived) Minor and transient changes in blood sugar (rare) AOD-9604 does not appear to cause the joint pain, fluid retention, or glucose dysregulation commonly seen with full hGH therapy